Nervous System Active Pharmaceutical Ingredients Market Report 2026

The nervous system active pharmaceutical ingredients market size has grown strongly in recent years. It will grow from $254.73 billion in 2025 to $268.45 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to rising neurological disorder prevalence, expansion of psychiatric drug use, growth of generic api manufacturing, increased cns drug approvals, expansion of contract api production.

The nervous system active pharmaceutical ingredients market size is expected to see strong growth in the next few years. It will grow to $334.12 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growth in neurodegenerative disease burden, expansion of specialty cns therapies, rising demand for high purity apis, increase in outsourced api manufacturing, growth of biologic neuro drugs. Major trends in the forecast period include high potency neurology api development, complex cns molecule synthesis, peptide based neuro apis, controlled release neuro api formats, specialized neuro api cdmo partnerships.

The rising prevalence of neurological disorders is anticipated to drive the growth of the nervous system active pharmaceutical ingredients market in the coming years. Neurological disorders refer to a wide range of medical conditions that impair the normal functioning of the central and peripheral nervous system, often resulting in symptoms such as seizures, paralysis, memory loss, or coordination difficulties. The prevalence of neurological disorders is increasing mainly due to the aging global population, as older individuals are more susceptible to neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease because nerve cells naturally decline and become more vulnerable over time. Nervous system active pharmaceutical ingredients support neurological disorders by modulating neural signaling and protecting nerve cells, thereby slowing disease progression and improving symptom management in conditions such as epilepsy, multiple sclerosis, and neurodegenerative diseases. For example, in December 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 425,000 Australians were living with dementia in 2024, and this number is projected to increase 2.5 times, reaching over 1.1 million by 2065, including roughly 662,000 women and 390,000 men. Therefore, the rising prevalence of neurological disorders is driving the growth of the nervous system active pharmaceutical ingredients market.

Companies operating in the nervous system active pharmaceutical ingredients market are focusing on developing innovative solutions, such as cannabinoid-based active pharmaceutical ingredients, to enhance the efficacy, safety, and targeted delivery of treatments for neurological disorders. Cannabinoid-based active pharmaceutical ingredients (APIs) are highly purified natural or synthetic compounds that deliver therapeutic effects by targeting the body’s endocannabinoid system to manage pain, epilepsy, nausea, and various neurological conditions. For example, in March 2024, Brains Bioceutical Corp., a Canada-based pharmaceutical company, launched solid D9 Tetrahydrocannabinol (THC), a cannabinoid-based active pharmaceutical ingredient designed to advance pharmaceutical research and drug development in neurological and pain management applications. This solid D9-THC API features a crystalline structure that improves storage stability and dosing accuracy over traditional cannabinoid extracts, facilitating its use in research and formulation development across therapeutic areas where CNS-active agents are critical. The product’s development underscores the shift toward more sophisticated API formats that can support precise, scalable pharmaceutical manufacturing.

In January 2025, Johnson & Johnson, a US-based healthcare technology and pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. Through this acquisition, Johnson & Johnson aimed to strengthen its neuroscience and central nervous system (CNS) therapeutic portfolio by incorporating new FDA-approved medicines and pipeline assets targeting psychiatric and neurodegenerative disorders, enhancing its capabilities in mental health and CNS drug development. Intra-Cellular Therapies Inc. is a US-based biopharmaceutical company that provides nervous system active pharmaceutical ingredients.

Major companies operating in the nervous system active pharmaceutical ingredients market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG., Thermo Fisher Scientific Inc., GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Zydus Lifesciences Limited, Biocon Ltd., Siegfried Holding AG., Alkem Laboratories Ltd., Almac Group, Torrent Pharmaceuticals Ltd., Granules India Ltd., Wockhardt Ltd., Neuland Laboratories Ltd., Hetero Labs Ltd., MSN Laboratories Pvt. Ltd., and Piramal Pharma.

Tariffs on pharmaceutical intermediates, specialty chemicals, and bulk drug substances are impacting the nervous system active pharmaceutical ingredients market by increasing input and production costs. Synthetic and high potency api segments that rely on imported intermediates are most affected. Regions dependent on cross border chemical supply chains, especially in asia and north america, face higher manufacturing expenses. These cost pressures can tighten margins for generic api producers. At the same time, tariffs are encouraging domestic api manufacturing expansion and backward integration into raw material production.

The nervous system active pharmaceutical ingredients market research report is one of a series of new reports that provides nervous system active pharmaceutical ingredients market statistics, including nervous system active pharmaceutical ingredients industry global market size, regional shares, competitors with a nervous system active pharmaceutical ingredients market share, detailed nervous system active pharmaceutical ingredients market segments, market trends and opportunities, and any further data you may need to thrive in the nervous system active pharmaceutical ingredients industry. This nervous system active pharmaceutical ingredients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nervous system active pharmaceutical ingredients are pharmacologically active compounds formulated to act on the central and peripheral nervous systems to diagnose, treat, prevent, or manage neurological and psychiatric disorders. These ingredients are intended for incorporation into finished dosage forms such as tablets, capsules, injectables, and liquid medicines used for treating nervous system-related conditions.

The key products of nervous system active pharmaceutical ingredients include cytokines, vaccines, fusion proteins, and therapeutic enzymes. Cytokines are protein-based molecules that regulate immune responses and are used to treat various neurological conditions. These products are produced using different expression systems, such as mammalian cells and microbial yeast. They are applied across multiple therapeutic areas, including diabetes, cardiovascular diseases, oncology, and neurological disorders, and are utilized by end users such as pharmaceutical companies, biopharmaceutical firms, contract development and manufacturing organizations, research and development laboratories, and generic drug manufacturers.

The nervous system active pharmaceutical ingredients market consists of sales of synthetic active pharmaceutical ingredients, biologically derived active pharmaceutical ingredients, generic active pharmaceutical ingredients, and branded active pharmaceutical ingredients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.